The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells
出版年份 2013 全文链接
标题
The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells
作者
关键词
-
出版物
Science Signaling
Volume 6, Issue 287, Pages ra66-ra66
出版商
American Association for the Advancement of Science (AAAS)
发表日期
2013-08-07
DOI
10.1126/scisignal.2004155
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks
- (2012) Michael J. Lee et al. CELL
- 2D protrusion but not motility predicts growth factor–induced cancer cell migration in 3D collagen
- (2012) Aaron S. Meyer et al. JOURNAL OF CELL BIOLOGY
- Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib
- (2012) Oana Pop et al. Journal of Thoracic Oncology
- Targeting Axl With an High-affinity Inhibitory Aptamer
- (2012) Laura Cerchia et al. MOLECULAR THERAPY
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- Rescue Screens with Secreted Proteins Reveal Compensatory Potential of Receptor Tyrosine Kinases in Driving Cancer Growth
- (2012) Fred Harbinski et al. Cancer Discovery
- Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer
- (2011) Chen-Yun Yeh et al. BMC CANCER
- Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design
- (2011) J. E. Chaft et al. CLINICAL CANCER RESEARCH
- Mena invasive (MenaINV) promotes multicellular streaming motility and transendothelial migration in a mouse model of breast cancer
- (2011) E. T. Roussos et al. JOURNAL OF CELL SCIENCE
- Signaling Network State Predicts Twist-Mediated Effects on Breast Cell Migration Across Diverse Growth Factor Contexts
- (2011) Hyung-Do Kim et al. MOLECULAR & CELLULAR PROTEOMICS
- An EMT–Driven Alternative Splicing Program Occurs in Human Breast Cancer and Modulates Cellular Phenotype
- (2011) Irina M. Shapiro et al. PLoS Genetics
- The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target
- (2010) Jan-Bart M. Koorstra et al. CANCER BIOLOGY & THERAPY
- A systems view of epithelial–mesenchymal transition signaling states
- (2010) Stuart Thomson et al. CLINICAL & EXPERIMENTAL METASTASIS
- Exon-Level Microarray Analyses Identify Alternative Splicing Programs in Breast Cancer
- (2010) A. Lapuk et al. MOLECULAR CANCER RESEARCH
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor
- (2010) D Ercan et al. ONCOGENE
- An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies
- (2010) X Ye et al. ONCOGENE
- Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer
- (2010) K Vuoriluoto et al. ONCOGENE
- Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes
- (2010) J. H. Taube et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab Therapy
- (2009) G. Zhuang et al. CANCER RESEARCH
- Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
- (2009) L. Liu et al. CANCER RESEARCH
- Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
- (2009) T. Arumugam et al. CANCER RESEARCH
- Epithelial-Mesenchymal Transitions in Development and Disease
- (2009) Jean Paul Thiery et al. CELL
- Twist1-Mediated Adriamycin-Induced Epithelial-Mesenchymal Transition Relates to Multidrug Resistance and Invasive Potential in Breast Cancer Cells
- (2009) Q.-Q. Li et al. CLINICAL CANCER RESEARCH
- BioNumbers—the database of key numbers in molecular and cell biology
- (2009) Ron Milo et al. NUCLEIC ACIDS RESEARCH
- Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis
- (2009) Y Li et al. ONCOGENE
- Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
- (2009) C. J. Creighton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival
- (2009) C. Gjerdrum et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival
- (2008) H. Jin et al. CANCER RESEARCH
- Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy
- (2008) Stuart Thomson et al. CLINICAL & EXPERIMENTAL METASTASIS
- Axl and Growth Arrest Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma Multiforme
- (2008) M. Hutterer et al. CLINICAL CANCER RESEARCH
- Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-κB and Brg-1
- (2008) K-Y Tai et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation